N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients
N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels are increased in patients with cancer. In this paper, we test whether NT-proBNP may identify patients who are going to receive a future cancer diagnosis (CD) in the intermediate-term follow-up. We studied 962 patients with stable cor...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/18/4042 |
id |
doaj-77fb0048148e40928833b86d69d77bd5 |
---|---|
record_format |
Article |
spelling |
doaj-77fb0048148e40928833b86d69d77bd52021-09-26T00:27:48ZengMDPI AGJournal of Clinical Medicine2077-03832021-09-01104042404210.3390/jcm10184042N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary PatientsJosé Tuñón0Ana Pello1Álvaro Aceña2Sergio Ramos-Cillán3Juan Martínez-Milla4Óscar González-Lorenzo5Jesús Fuentes-Antras6Nieves Tarín7Carmen Cristóbal8Luis M. Blanco-Colio9José Luis Martín-Ventura10Ana Huelmos11Carlos Gutiérrez-Landaluce12Marta López-Castillo13Joaquín Alonso14Lorenzo López Bescós15Jesús Egido16Ignacio Mahíllo-Fernández17Óscar Lorenzo18Department of Cardiology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Cardiology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Cardiology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Medicine, School of Medicine, Autónoma University, 28040 Madrid, SpainDepartment of Cardiology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Cardiology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Oncology, Hospital Clínico Universitario San Carlos, 28040 Madrid, SpainDepartment of Cardiology, Hospital Universitario de Móstoles, 28040 Madrid, SpainDepartment of Cardiology, Hospital de Fuenlabrada, 28040 Madrid, SpainLaboratory of Vascular Pathology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Medicine, School of Medicine, Autónoma University, 28040 Madrid, SpainDepartment of Cardiology, Hospital Universitario Fundación Alcorcón, 28040 Madrid, SpainDepartment of Cardiology, Hospital de Fuenlabrada, 28040 Madrid, SpainDepartment of Cardiology, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Medicine, School of Medicine, Rey Juan Carlos University, Alcorcón, 28040 Madrid, SpainDepartment of Medicine, School of Medicine, Rey Juan Carlos University, Alcorcón, 28040 Madrid, SpainDepartment of Medicine, School of Medicine, Autónoma University, 28040 Madrid, SpainResearch Unit, IIS-Fundación Jiménez Díaz, 28040 Madrid, SpainDepartment of Medicine, School of Medicine, Autónoma University, 28040 Madrid, SpainN-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels are increased in patients with cancer. In this paper, we test whether NT-proBNP may identify patients who are going to receive a future cancer diagnosis (CD) in the intermediate-term follow-up. We studied 962 patients with stable coronary artery disease and free of cancer and heart failure at baseline. This sample represents a re-analysis of a previous work expanding the sample size and the follow-up. NT-proBNP, galectin-3, monocyte chemoattractant protein-1, high-sensitivity C-reactive protein, high-sensitivity cardiac troponin I (hsTnI), and calcidiol (vitamin D) plasma levels were assessed. The primary outcome was new CD. After 5.40 (2.81–6.94) years of follow-up, 59 patients received a CD. NT-proBNP [HR 1.036 CI (1.015–1.056) per increase in 100 pg/mL; <i>p</i> = 0.001], previous atrial fibrillation (HR 3.140 CI (1.196–8.243); <i>p</i> = 0.020), and absence of previous heart failure (HR 0.067 CI (0.006–0.802); <i>p</i> = 0.033) were independent predictors of receiving a CD in the first three years of follow-up. None of the variables analyzed predicted a CD beyond this time. The number of patients developing heart failure during follow-up was 0 (0.0%) in patients receiving CD in the first three years of follow-up, 2 (6.9%) in those receiving a CD diagnosis beyond this time, and 40 (4.4%) in patients not developing cancer (<i>p</i> = 0.216). These numbers suggest that future heart failure was not a confounding factor. In patients with coronary artery disease, NT-proBNP was an independent predictor of CD in the first three years of follow-up but not later, suggesting that it could be detecting subclinical undiagnosed cancers.https://www.mdpi.com/2077-0383/10/18/4042coronary artery diseaseN-terminal pro-brain natriuretic peptidecancertumorbiomarker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
José Tuñón Ana Pello Álvaro Aceña Sergio Ramos-Cillán Juan Martínez-Milla Óscar González-Lorenzo Jesús Fuentes-Antras Nieves Tarín Carmen Cristóbal Luis M. Blanco-Colio José Luis Martín-Ventura Ana Huelmos Carlos Gutiérrez-Landaluce Marta López-Castillo Joaquín Alonso Lorenzo López Bescós Jesús Egido Ignacio Mahíllo-Fernández Óscar Lorenzo |
spellingShingle |
José Tuñón Ana Pello Álvaro Aceña Sergio Ramos-Cillán Juan Martínez-Milla Óscar González-Lorenzo Jesús Fuentes-Antras Nieves Tarín Carmen Cristóbal Luis M. Blanco-Colio José Luis Martín-Ventura Ana Huelmos Carlos Gutiérrez-Landaluce Marta López-Castillo Joaquín Alonso Lorenzo López Bescós Jesús Egido Ignacio Mahíllo-Fernández Óscar Lorenzo N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients Journal of Clinical Medicine coronary artery disease N-terminal pro-brain natriuretic peptide cancer tumor biomarker |
author_facet |
José Tuñón Ana Pello Álvaro Aceña Sergio Ramos-Cillán Juan Martínez-Milla Óscar González-Lorenzo Jesús Fuentes-Antras Nieves Tarín Carmen Cristóbal Luis M. Blanco-Colio José Luis Martín-Ventura Ana Huelmos Carlos Gutiérrez-Landaluce Marta López-Castillo Joaquín Alonso Lorenzo López Bescós Jesús Egido Ignacio Mahíllo-Fernández Óscar Lorenzo |
author_sort |
José Tuñón |
title |
N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients |
title_short |
N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients |
title_full |
N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients |
title_fullStr |
N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients |
title_full_unstemmed |
N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients |
title_sort |
n-terminal pro-brain natriuretic peptide plasma levels are associated with intermediate-term follow-up cancer in coronary patients |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-09-01 |
description |
N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels are increased in patients with cancer. In this paper, we test whether NT-proBNP may identify patients who are going to receive a future cancer diagnosis (CD) in the intermediate-term follow-up. We studied 962 patients with stable coronary artery disease and free of cancer and heart failure at baseline. This sample represents a re-analysis of a previous work expanding the sample size and the follow-up. NT-proBNP, galectin-3, monocyte chemoattractant protein-1, high-sensitivity C-reactive protein, high-sensitivity cardiac troponin I (hsTnI), and calcidiol (vitamin D) plasma levels were assessed. The primary outcome was new CD. After 5.40 (2.81–6.94) years of follow-up, 59 patients received a CD. NT-proBNP [HR 1.036 CI (1.015–1.056) per increase in 100 pg/mL; <i>p</i> = 0.001], previous atrial fibrillation (HR 3.140 CI (1.196–8.243); <i>p</i> = 0.020), and absence of previous heart failure (HR 0.067 CI (0.006–0.802); <i>p</i> = 0.033) were independent predictors of receiving a CD in the first three years of follow-up. None of the variables analyzed predicted a CD beyond this time. The number of patients developing heart failure during follow-up was 0 (0.0%) in patients receiving CD in the first three years of follow-up, 2 (6.9%) in those receiving a CD diagnosis beyond this time, and 40 (4.4%) in patients not developing cancer (<i>p</i> = 0.216). These numbers suggest that future heart failure was not a confounding factor. In patients with coronary artery disease, NT-proBNP was an independent predictor of CD in the first three years of follow-up but not later, suggesting that it could be detecting subclinical undiagnosed cancers. |
topic |
coronary artery disease N-terminal pro-brain natriuretic peptide cancer tumor biomarker |
url |
https://www.mdpi.com/2077-0383/10/18/4042 |
work_keys_str_mv |
AT josetunon nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT anapello nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT alvaroacena nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT sergioramoscillan nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT juanmartinezmilla nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT oscargonzalezlorenzo nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT jesusfuentesantras nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT nievestarin nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT carmencristobal nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT luismblancocolio nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT joseluismartinventura nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT anahuelmos nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT carlosgutierrezlandaluce nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT martalopezcastillo nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT joaquinalonso nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT lorenzolopezbescos nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT jesusegido nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT ignaciomahillofernandez nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients AT oscarlorenzo nterminalprobrainnatriureticpeptideplasmalevelsareassociatedwithintermediatetermfollowupcancerincoronarypatients |
_version_ |
1717366076419866624 |